Furthermore, it was recently shown that antisense oligonucleotide treatment to decrease Scn8a (Nav1.6) expression was sufficient to rescue disease phenotypes in a Dravet Syndrome model of Scn1a haploinsufficiency [52]. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.